HBV Mutation Detail Information

Virus Mutation HBV Mutation 131_133ins


I; (12) s122-123 ""KSTGLCK"" insertion+sQ129N; and (13) preS2 initiation codon M-->I+s131-133TSM-->NST. --> I; (12) s122-123 ""KSTGLCK"" insertion+sQ129N; and (13) preS2 initiation codon M-->I+s131-133TSM-->NST. -->
Basic Characteristics of Mutations
Mutation Site 131_133ins
Mutation Site Sentence RESULTS: Twenty-one preS/S-gene mutants were cloned from four sequential serum samples, including 13 mutants that were not previously documented: (1) sI/T126V+sG145R; (2) preS1 nt 3014-3198 deletion; (3) preS1 nt 3046-3177 deletion; (4) preS1 nt 3046-3177 deletion+s115-116 ""INGTST"" insertion; (5) preS1 nt 3046-3177 deletion+s115-116 ""INGTST"" insertion+sG145R; (6) preS1 nt 3115-3123 deletion+sQ129N; (7) preS1 nt 3115-3123 deletion+s126-127 ""RPCMNCTI"" insertion; (8) s115-116 ""INGTST"" insertion; (9) s115-116 ""INGTST"" insertion+sG145R; (10) s126-127 ""RPCMNCTI"" insertion; (11) preS1 nt 2848-2862 deletion+preS2 initiation codon M-->I; (12) s122-123 ""KSTGLCK"" insertion+sQ129N; and (13) preS2 initiation codon M-->I+s131-133TSM-->NST.
Mutation Level Amino acid level
Mutation Type Insertion
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype C
Viral Reference Y18856
Functional Impact and Mechanisms
Disease Occult HBV Infection    
Immune Y
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment -
Location China
Literature Information
PMID 27182775
Title Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection
Author Chen J,Liu Y,Zhao J,Xu Z,Chen R,Si L,Lu S,Li X,Wang S,Zhang K,Li J,Han J,Xu D
Journal PloS one
Journal Info 2016 May 16;11(5):e0155654
Abstract OBJECTIVE: The impact of hepatitis B virus (HBV) preS/S-gene mutations on occult HBV infection (OBI) is not fully understood. This study characterized multiple novel HBV preS/S-gene mutants obtained from an OBI patient. METHODS: PreS/S-gene mutants were analyzed by clonal sequencing. Viral replication and expression were analyzed by transfecting HBV genomic recombinants into HepG2 cells. RESULTS: Twenty-one preS/S-gene mutants were cloned from four sequential serum samples, including 13 mutants that were not previously documented: (1) sI/T126V+sG145R; (2) preS1 nt 3014-3198 deletion; (3) preS1 nt 3046-3177 deletion; (4) preS1 nt 3046-3177 deletion+s115-116 ""INGTST"" insertion; (5) preS1 nt 3046-3177 deletion+s115-116 ""INGTST"" insertion+sG145R; (6) preS1 nt 3115-3123 deletion+sQ129N; (7) preS1 nt 3115-3123 deletion+s126-127 ""RPCMNCTI"" insertion; (8) s115-116 ""INGTST"" insertion; (9) s115-116 ""INGTST"" insertion+sG145R; (10) s126-127 ""RPCMNCTI"" insertion; (11) preS1 nt 2848-2862 deletion+preS2 initiation codon M-->I; (12) s122-123 ""KSTGLCK"" insertion+sQ129N; and (13) preS2 initiation codon M-->I+s131-133TSM-->NST. The proportion of preS1 nt 3046-3177 deletion and preS2 initiation codon M-->I+s131-133TSM-->NST mutants increased in the viral pool with prolonged disease. The 13 novel OBI-related mutants showed a 51.2-99.9% decrease in HBsAg levels compared with that of the wild type. Additional N-glycosylation-associated mutations, sQ129N and s131-133TSM-->NST, but not s126-127 ""RPCMNCTI,"" greatly attenuated anti-HBs binding to HBsAg. Compared with the wild type, replication and surface antigen promoter II activity of the preS1 nt 3046-3177 deletion mutant decreased by 43.3% and 97.0%, respectively. CONCLUSION: PreS/S-gene mutations may play coordinated roles in the presentation of OBI and might be associated with disease progression. This has implications for HBV diagnosis and vaccine improvement.
Sequence Data KR014142
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.